Aurisco's first oligonucleotide commercial manufacturing line was successfully delivered by Cytiva, accelerating the commercialization process of oligonucleotide drugs.The project was efficiently completed in less than 18 months, with strong support from Cytiva, and Aurisco's oligonucleotide commercial manufacturing line was successfully launched. Aurisco and Cytiva are deepening their cooperation to jointly promote the development and commercialization of oligonucleotide drugs, bringing transformative therapies to patients worldwide.

September 30, 2024, in the High-Tech Industrial Development Zone of Yangzhou, Jiangsu Province, China, with the strong support of global life sciences leader Cytiva, Aurisco Pharmaceutical Co., Ltd. completed its first FlexFactory oligonucleotide commercial manufacturing line within 18 months. The establishment of this Oligo FlexFactory commercial manufacturing line provides Aurisco with a high-quality, stable production platform, accelerating the company's progress in the commercialization of ASO, naked and conjugated siRNA, aptamers and other oligonucleotide drugs, injecting new momentum into the company's development in the international oligonucleotide business sector.

In this collaboration, Cytiva provided Aurisco with its first commercial Oligo FlexFactory production line, along with professional technical and service support, leveraging its extensive experience and comprehensive enterprise solution platform. Cytiva’s expert team managed the entire project, from plant process design to the delivery of core process equipment, ensuring the successful implementation of the project. They effectively controlled the budget, delivery timeline, and project deviations, providing Aurisco with full lifecycle project management. Cytiva's VIP after-sales services, including trial batch process training, comprehensive technical support, and talent training, will provide a solid foundation for the continuous and stable operation of Aurisco’s oligonucleotide commercial manufacturing line.

Aurisco's first Oligo FlexFactory commercial manufacturing line meets the growing market demand and provides strong support to the company in expanding its diversified oligonucleotide drug business. Aurisco looks forward to further deepening its cooperation with Cytiva, jointly promoting the safety and efficiency of oligonucleotide drug research and production, so that these therapies can benefit more patients.

About Cytiva

Cytiva is a global Pioneer in the life sciences field, with approximately 15,000 employees in over 40 countries and regions worldwide, dedicated to advancing unseen technologies and accelerating extraordinary therapies. As a trusted partner, Cytiva actively collaborates with researchers in academia and translational medicine, as well as biotech developers and manufacturers. The company focuses on biologics, cell and gene therapies, and a range of innovative technologies, including mRNA. By enhancing the capability, speed, efficiency, and flexibility of drug development and bioprocessing, Cytiva is committed to developing and producing transformative medicines and therapies that benefit patients around the world.